论文部分内容阅读
目的:探讨冠心病非经皮冠状动脉介入治疗对患者血浆同型半胱氨酸(Hcy)水平及C反应蛋白的变化。方法:选择2015年1月~2015年9月我院住院的182例冠心病患者为研究对象,采用简单随机分组法,分为对照组和观察组各91例,对照组给予常规药物治疗,观察组在对照组基础上给予阿托伐他汀钙片,观察两组治疗2个月及1年后的近远期疗效及治疗前后的血浆Hcy水平和C反应蛋白。结果:治疗后观察组总有效率高于对照组。观察组与对照组治疗后的血浆Hcy及C反应蛋白水平都明显低于治疗前,且观察组明显少于对照组。随访调查1年,观察组的心性猝死、心衰、心肌梗塞、心肌血运重建等并发症发生率为4.4%,对照组为14.3%,观察组的明显少于对照组。结论:冠心病非经皮冠状动脉介入治疗比较常见,阿托伐他汀的应用能提高治疗的近远期效果,其作用机制可能与促进血浆同型半胱氨酸及C反应蛋白表达下降有关。
Objective: To investigate the changes of plasma homocysteine (Hcy) level and C-reactive protein in patients with coronary artery disease undergoing non-percutaneous coronary intervention. Methods: A total of 182 coronary heart disease patients hospitalized in our hospital from January 2015 to September 2015 were selected as study subjects. The subjects were divided into control group and observation group, with 91 cases in each group. The control group was given routine drug treatment and observation Atorvastatin calcium tablets were given on the basis of the control group. The short-term and long-term effects and the levels of plasma Hcy and C-reactive protein in both groups were observed at 2 months and 1 year after treatment. Results: The total effective rate of observation group after treatment was higher than that of control group. The levels of plasma Hcy and C-reactive protein in observation group and control group were significantly lower than before treatment, and the observation group was significantly less than the control group. Follow-up survey for 1 year, the observation group sudden cardiac death, heart failure, myocardial infarction, myocardial revascularization and other complications was 4.4% in the control group was 14.3%, the observation group was significantly less than the control group. Conclusion: Non-percutaneous coronary intervention in coronary heart disease is relatively common. The application of atorvastatin can improve the short-term and long-term effects of treatment. Its mechanism may be related to the decrease of plasma homocysteine and C-reactive protein expression.